Status:
COMPLETED
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Lead Sponsor:
Laboratorios Silanes S.A. de C.V.
Conditions:
Dyslipidemias
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medic...
Detailed Description
To assess the safety of the fixed-dose combination of rosuvastatin / ezetimibe in subjects older than 18 years of age (gender indistinct) with dyslipidemia who at the discretion have been candidates f...
Eligibility Criteria
Inclusion
- Age\> 18 years of age.
- Diagnosis of dyslipidemia.
- That treatment with the fixed-dose combination of rosuvastatin / ezetimibe is documented.
- Have security questioning on at least two occasions.
Exclusion
- Subjects who has taken any other statins, fibrates, bile acid sequestrants, niacin (\> 500 mg) or inhibitors of PCSK9 concomitantly during treatment with rosuvastatin / ezetimibe.
Key Trial Info
Start Date :
September 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04862962
Start Date
September 30 2021
End Date
February 15 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico, 11000